Please assess the completion status of the following clinical trial:

Trial Title: G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hematologic malignancies or bone marrow failure syndrome who are candidates for allogeneic bone marrow transplantation are eligible for this study. Hematologic malignancies indicated for transplantation:~  * Acute lymphoblastic leukemia (ALL) in first remission (with high risk feature), 2nd or greater remission.~ * Acute myeloid leukemia (AML) in first remission (with high risk feature), 2nd or greater remission.~ * Chronic myeloid leukemia (CML) in 2nd chronic phase or accelerated phase.~ * Juvenile myelomonocytic leukemia (JMML).~ * Myelodysplastic syndrome.~ * Biphenotypic leukemia in first (with high risk feature), 2nd or greater remission.~ * Induction failure leukemia.~ * Refractory relapsed leukemia.~ * Bone marrow failure syndrome.~ * Severe aplastic anemia failed immunotherapy.~* Patients who do not have a 6 out of 6 matched related or unrelated donor or 4/6 and 5/6 matched cord blood will be eligible for this study.~* Partially mismatched related donor availability as defined by molecular typing with 3 to 5 HLA matches.~* Patients who are under 22 years of age.~Exclusion Criteria:~* Patients will not be excluded based on sex, racial, or ethnic background.~* Patients will be excluded if they demonstrate significant functional deficits in major organs, which would obviously interfere with successful outcome following bone marrow transplant utilizing the following guidelines.~  * Evidence of active, deep-seated, life-threatening infections for which there is no known effective therapy (certain fungal species, HIV, etc.).~ * Patients who have been treated for infections must have appropriate responses as documented by 2 (two) consecutive negative cultures and/or stable radiographic examinations.~ * Patients who have active central nervous system (CNS) leukemic disease.~* Patients will be excluded if they are women of childbearing potential who are currently pregnant (beta-HCG+) or who are not practicing adequate contraception.~* Patients who have had a previous hematopoietic stem cell transplant will be excluded.~* Donors will be excluded if they are sensitive to E. coli-derived protein.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- Granulocyte Colony Stimulating Factor (G-CSF) stimulation (Type: OTHER): Participants will receive bone marrow from donors who undergo Granulocyte Colony Stimulating Factor (G-CSF) stimulation prior to bone marrow collection.

Based on this trial design, predict the completion outcome and termination type (if applicable).